Editorial
|
|
|
Unethical trials and reckless doctors
|
|
|
New Products
|
|
|
Avoid cox-2 inhibitors for pain
|
|
|
|
|
|
|
For some overweight patients
|
|
|
|
|
|
|
No proof of reduced risk of self-administered injection
|
|
|
|
|
|
Me-too available in single dose strength only
|
|
|
|
|
|
Just a metabolite of risperidone
|
|
|
|
|
|
|
|
|
Minimally assessed me-toos
|
|
|
|
|
|
|
|
|
Complicated cutaneous and intra-abdominal infections: no progress
|
|
|
|
|
|
Severe gram-positive infections: no advantage, but risk of muscle disorders
|
|
|
|
|
|
|
|
|
|
|
Reviews
|
|
|
Interferon beta for some serious forms
|
|
|
|
|
|
|
Increased susceptibility to pneumonia
|
|
|
|
|
|
Behavioural management can help
|
|
|
|
|
|
No preventive effect for ramipril and cardiac adverse effects for rosiglitazone
|
|
|
|
|
|
|